Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

Inclusion Criteria:

• Adult male 18 years or older
• Histopathologically-proven PCa
• Unfavorable IR to HR disease:
• Prostate specific antigen (PSA) >= 10 ng/mL
• Or cT-stage >= 2b
• Or Gleason grade 3 (4+3=7) or higher
• Or Gleason grade 2 (3+4=7) AND >= 50% positive biopsy cores
• Or Decipher Score >= 0.45
• Treating radiation oncologist intends to incorporate PSMA PET findings into theradiotherapy plan, if patient undergoes PSMA PET (intervention arm 2)
• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for theduration of the study

Exclusion Criteria:

• Less than 18 years old at the time of investigational product administration
• Extra-pelvic metastasis (M1 disease) on any imaging or biopsy done beforerandomization
• Prior PSMA PET
• Prior pelvic RT
• Contraindications to radiotherapy (including active inflammatory bowel disease)
• Concurrent or prior surgery or systemic therapy for PCa at the time of randomization